Li Xiao-hong, Fu Yong-heng, Liu Zai-yi, Zhang Guang-feng, Dong Guang-fu, Lin Qiu-xiong, Yu Xi-yong
Guangdong Provincial Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Aug;37(8):680-4.
To compare the efficacy of transplanting bone marrow mesenchymal stem cell (BMSC) or microenvironmental induced BMSC (iBMSC) into the ischemic myocardium of rats with myocardial infarction.
iBMSC was defined as BMSC co-cultured with myocardial cells for 2 weeks. The stem cells or equal volume PBS were injected into ischemic border zone 1 wk after experimental infarction. Cardiac performance was evaluated at 1, 2, and 4 wk after cell transplantation by echocardiography and analyzed histologically at 4 wk after cell transplantations.
Compared with PBS group, both BMSC and iBMSC transplantations reduced infarct size. iBMSC enhanced the beneficial effects of BMSC on improving cardiac function (FS: 28.5% +/- 4.3% in PBS, 29.0% +/- 2.0% in BMSC and 45.1% +/- 3.1% in iBMSC group at 4 weeks post transplantation, iBMSC group vs. PBS group P < 0.05, iBMSC group vs. BMSC group P < 0.05). Immunofluorescence microscopy results revealed co-localization of SPIO-labeled transplanted cells with cardiac markers for cardiomyocytes, indicating regeneration of damaged myocardium.
Our data suggest that iBMSC implantation is more effective on improving cardiac function than BMSC implantation in this model. iBMSC might serve as a new promising therapeutic cell source for regenerating ischemic myocardium in patients with post-infarction heart failure.
比较将骨髓间充质干细胞（BMSC）或微环境诱导的BMSC（iBMSC）移植到心肌梗死大鼠缺血心肌中的疗效。
iBMSC定义为与心肌细胞共培养2周的BMSC。在实验性梗死1周后，将干细胞或等体积的磷酸盐缓冲盐水（PBS）注入缺血边界区。在细胞移植后1、2和4周通过超声心动图评估心脏功能，并在细胞移植后4周进行组织学分析。
与PBS组相比，BMSC和iBMSC移植均减小了梗死面积。iBMSC增强了BMSC对改善心脏功能的有益作用（移植后4周时，PBS组的左室短轴缩短率（FS）为28.5%±4.3%，BMSC组为29.0%±2.0%，iBMSC组为45.1%±3.1%，iBMSC组与PBS组比较，P<0.05，iBMSC组与BMSC组比较，P<0.05）。免疫荧光显微镜检查结果显示，超顺磁性氧化铁（SPIO）标记的移植细胞与心肌细胞的心脏标志物共定位，表明受损心肌发生了再生。
我们的数据表明，在该模型中，iBMSC植入在改善心脏功能方面比BMSC植入更有效。iBMSC可能作为一种新的有前景的治疗细胞来源，用于梗死性心力衰竭患者缺血心肌的再生。
